{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:42:19Z","timestamp":1790221339153,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jtct.2024.09.017","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T12:32:16Z","timestamp":1726835536000},"page":"1155-1170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8767-3491","authenticated-orcid":false,"given":"Raheel","family":"Iftikhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-8974","authenticated-orcid":false,"given":"Zachariah","family":"DeFilipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"DeZern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-8420","authenticated-orcid":false,"given":"Michael A.","family":"Pulsipher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelli","family":"Bejanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri M.","family":"Burroughs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adetola","family":"Kassim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blachy J. D\u00e1vila","family":"Salda\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3942-7370","authenticated-orcid":false,"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4627-1714","authenticated-orcid":false,"given":"Joseph H.","family":"Antin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jtct.2024.09.017_bib0001","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.13853","article-title":"Guidelines for the diagnosis and management of adult aplastic anaemia","volume":"172","author":"Killick","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jtct.2024.09.017_bib0002","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/bjh.19236","article-title":"Guidelines for the diagnosis and management of adult aplastic anaemia: a British Society for Haematology Guideline","volume":"204","author":"Kulasekararaj","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2024.09.017_bib0003","first-page":"810","article-title":"GRADE methods for guideline development: time to evolve?","author":"Norris","year":"2016","journal-title":"Am Coll Phys"},{"key":"10.1016\/j.jtct.2024.09.017_bib0004","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ, Al-Ansary LA, Forland F, et al. Guidelines International Network: principles for disclosure of interests and management of conflicts in guidelines. 2015;163(7):548-53.","DOI":"10.7326\/M14-1885"},{"key":"10.1016\/j.jtct.2024.09.017_bib0005","doi-asserted-by":"crossref","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. 2008;336(7650):924-6.","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"10.1016\/j.jtct.2024.09.017_bib0006","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jtct.2024.09.017_bib0007","doi-asserted-by":"crossref","unstructured":"Aguayo-Albasini JL, Flores-Pastor B, Soria-Aledo VJCE. GRADE system: classification of quality of evidence and strength of recommendation. 2014;92(2):82-8.","DOI":"10.1016\/j.cireng.2013.08.002"},{"key":"10.1016\/j.jtct.2024.09.017_bib0008","unstructured":"Available from: https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html#h.xr5ac2p2khuq (accessed October 16, 2024)."},{"issue":"1","key":"10.1016\/j.jtct.2024.09.017_bib0009","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/16078454.2019.1711344","article-title":"Epidemiology of aplastic anemia: a study of 1324 cases","volume":"25","author":"Ahmed","year":"2020","journal-title":"Hematology"},{"issue":"12","key":"10.1016\/j.jtct.2024.09.017_bib0010","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1182\/bloodadvances.2021004345","article-title":"Approach to the diagnosis of aplastic anemia","volume":"5","author":"DeZern","year":"2021","journal-title":"Blood Adv"},{"issue":"S1","key":"10.1016\/j.jtct.2024.09.017_bib0011","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5045\/br.2022.2022012","article-title":"Overview of inherited bone marrow failure syndromes","volume":"57","author":"Park","year":"2022","journal-title":"Blood Res"},{"issue":"15","key":"10.1016\/j.jtct.2024.09.017_bib0012","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/bloodadvances.2018021162","article-title":"Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment","volume":"2","author":"Georges","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2024.09.017_bib0013","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.seminhematol.2019.03.004","article-title":"Haploidentical donor transplants for severe aplastic anemia","volume":"56","author":"Bacigalupo","year":"2019","journal-title":"Semin Hematol"},{"issue":"5","key":"10.1016\/j.jtct.2024.09.017_bib0014","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3324\/haematol.2014.115345","article-title":"Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis","volume":"100","author":"Bacigalupo","year":"2015","journal-title":"haematologica"},{"issue":"12","key":"10.1016\/j.jtct.2024.09.017_bib0015","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.bbmt.2019.07.029","article-title":"Outcome of Fludarabine-based conditioning in high-risk aplastic anemia patients undergoing matched related donor transplantation: a single-center study from Pakistan","volume":"25","author":"Chaudhry","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2024.09.017_bib0016","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.3324\/haematol.2014.106096","article-title":"Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"99","author":"Dufour","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jtct.2024.09.017_bib0017","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1182\/asheducation-2005.1.110","article-title":"Aplastic anemia: management of adult patients","author":"Maciejewski","year":"2005","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2024.09.017_bib0018","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/asheducation-2011.1.90","article-title":"Clonal evolution in aplastic anemia","volume":"2011","author":"Afable","year":"2011","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2024.09.017_bib0019","article-title":"Comparisons between frontline therapy and a combination of eltrombopag plus immunosuppression therapy and human leukocyte antigen-haploidentical hematopoietic stem cell transplantation in patients with severe aplastic anemia: a systematic review","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"issue":"20","key":"10.1016\/j.jtct.2024.09.017_bib0020","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2019000722","article-title":"Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia","volume":"3","author":"Bejanyan","year":"2019","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.jtct.2024.09.017_bib0021","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2017-09-807859","article-title":"Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?","volume":"131","author":"Giammarco","year":"2018","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.jtct.2024.09.017_bib0022","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1182\/bloodadvances.2019000480","article-title":"Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years","volume":"3","author":"Sheth","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2024.09.017_bib0023","doi-asserted-by":"crossref","unstructured":"Shin S, Jeon Y, Yoon J, et al. Comparable outcomes between younger (\u2a7d 40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning. 2016;51(11): 1456-63.","DOI":"10.1038\/bmt.2016.171"},{"issue":"3","key":"10.1016\/j.jtct.2024.09.017_bib0024","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.bbmt.2018.08.029","article-title":"Allogeneic hematopoietic cell transplantation in patients aged 50years or older with severe aplastic anemia","volume":"25","author":"Rice","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2024.09.017_bib0025","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.bbmt.2018.08.029","article-title":"Allogeneic hematopoietic cell transplantation in patients aged 50years or older with severe aplastic anemia","volume":"25","author":"Rice","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2024.09.017_bib0026","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/bmt.2016.171","article-title":"Comparable outcomes between younger (40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning","volume":"51","author":"Shin","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2024.09.017_bib0027","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.3324\/haematol.2010.026682","article-title":"Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors","volume":"95","author":"Gupta","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2024.09.017_bib0028","doi-asserted-by":"crossref","unstructured":"Devillier R, Dalle J-H, Kulasekararaj A, et al. Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society of Bone Marrow Transplantation and Cell Therapies and the EBMT Severe Aplastic Anemia Working Party. 2016;101(7):884.","DOI":"10.3324\/haematol.2015.138727"},{"issue":"7","key":"10.1016\/j.jtct.2024.09.017_bib0029","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3324\/haematol.2015.138727","article-title":"Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society of Bone Marrow Transplantation and Cell Therapies and the EBMT Severe Aplastic Anemia Working Party","volume":"101","author":"Devillier","year":"2016","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.jtct.2024.09.017_bib0030","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/bmt.2016.171","article-title":"Comparable outcomes between younger (\u2a7d40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning","volume":"51","author":"Shin","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2024.09.017_bib0031","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.bbmt.2012.03.015","article-title":"Allogeneic hematopoietic stem cell transplant for adults over 40 years old with acquired aplastic anemia","volume":"18","author":"Kim","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.09.017_bib0032","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.284022","article-title":"Uniform conditioning regardless of donor in bone marrow transplantation for severe aplastic anemia","author":"DeZern","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jtct.2024.09.017_bib0033","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bcmd.2015.03.007","article-title":"Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP)","volume":"55","author":"Barone","year":"2015","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"10.1016\/j.jtct.2024.09.017_bib0034","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/bjh.13297","article-title":"Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant","volume":"169","author":"Dufour","year":"2015","journal-title":"British Journal Haematol"},{"issue":"7","key":"10.1016\/j.jtct.2024.09.017_bib0035","doi-asserted-by":"crossref","first-page":"e13552","DOI":"10.1111\/petr.13552","volume":"23","author":"Darrigo","year":"2019","journal-title":"Pediatr Transplant"},{"issue":"7\u20138","key":"10.1016\/j.jtct.2024.09.017_bib0036","first-page":"16448","article-title":"Allogeneic hematopoietic stem cell transplantation for acquired severe aplastic anemia: a summary of a 20-year experience","volume":"133","author":"Zieli\u0144ska","year":"2023","journal-title":"Polish Arch Int Med"},{"issue":"1","key":"10.1016\/j.jtct.2024.09.017_bib0037","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2021012130","article-title":"Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study","volume":"139","author":"Patel","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2024.09.017_bib0038","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3324\/haematol.2014.115345","article-title":"Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis","volume":"100","author":"Bacigalupo","year":"2015","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.jtct.2024.09.017_bib0039","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","article-title":"Eltrombopag added to standard immunosuppression for aplastic anemia","volume":"376","author":"Townsley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.09.017_bib0040","doi-asserted-by":"crossref","unstructured":"Groarke EM, Patel BA, Gutierrez-Rodrigues F, et al. Eltrombopag added to immunosuppression for children with treatment-na\u00efve severe aplastic anaemia. 2021;192(3):605-14.","DOI":"10.1111\/bjh.17232"},{"issue":"1","key":"10.1016\/j.jtct.2024.09.017_bib0041","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12865-020-0340-x","article-title":"Allo-HSCT compared with immunosuppressive therapy for acquired aplastic anemia: a system review and meta-analysis","volume":"21","author":"Zhu","year":"2020","journal-title":"BMC Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2024.09.017_bib0042","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-022-01324-1","article-title":"Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study","volume":"15","author":"Liu","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2024.09.017_bib0043","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF02983381","article-title":"Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation: multicenter trial","volume":"78","author":"Ahn","year":"2003","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2024.09.017_bib0044","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3346\/jkms.2003.18.3.365","article-title":"The treatment of severe aplastic anemia: outcomes of bone marrow transplantation and immunosuppressive therapy in a single institution of Korea","volume":"18","author":"Kim","year":"2003","journal-title":"J Korean Med Sci"},{"issue":"1","key":"10.1016\/j.jtct.2024.09.017_bib0045","first-page":"321","article-title":"Long-term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation","volume":"111","author":"Kojima","year":"2000","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.jtct.2024.09.017_bib0046","doi-asserted-by":"crossref","first-page":"586.e1","DOI":"10.1016\/j.jtct.2022.05.027","article-title":"Frontline therapy options for adults with newly diagnosed severe aplastic anemia: intensive immunosuppressive therapy plus eltrombopag or matched sibling donor hematopoietic stem cell transplantation?","volume":"28","author":"Huang","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.09.017_bib0047","doi-asserted-by":"crossref","unstructured":"Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation. 2007;92(1):11-8.","DOI":"10.3324\/haematol.10075"},{"issue":"6","key":"10.1016\/j.jtct.2024.09.017_bib0048","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1182\/blood-2011-12-274019","article-title":"How I treat acquired aplastic anemia","volume":"120","author":"Scheinberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.09.017_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100772","article-title":"Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies","volume":"47","author":"Iftikhar","year":"2021","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.jtct.2024.09.017_bib0050","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.hoc.2018.04.001","article-title":"Haploidentical donor bone marrow transplantation for severe aplastic anemia","volume":"32","author":"DeZern","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"25","key":"10.1016\/j.jtct.2024.09.017_bib0051","first-page":"3031","article-title":"Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia","volume":"141","author":"DeZern","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2024.09.017_bib0052","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/bjh.13614","volume":"171","author":"Dufour","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2024.09.017_bib0053","doi-asserted-by":"crossref","unstructured":"Samarasinghe S, Veys P, Vora A, Wynn RJBJoH. Paediatric amendment to adult BSH Guidelines for aplastic anaemia. 2018;180(2):201-5.","DOI":"10.1111\/bjh.15066"},{"issue":"10","key":"10.1016\/j.jtct.2024.09.017_bib0054","doi-asserted-by":"crossref","first-page":"e28444","DOI":"10.1002\/pbc.28444","volume":"67","author":"Pulsipher","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"10.1016\/j.jtct.2024.09.017_bib0055","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(22)00206-X","article-title":"Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial","volume":"9","author":"DeZern","year":"2022","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.jtct.2024.09.017_bib0056","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/s41409-019-0773-0","article-title":"Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party","volume":"55","author":"Prata","year":"2020","journal-title":"Bone Marrow Transplantation"},{"issue":"2","key":"10.1016\/j.jtct.2024.09.017_bib0057","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13179","article-title":"First-line choice for severe aplastic anemia in children: Transplantation from a haploidentical donor vs immunosuppressive therapy","volume":"32","author":"Cheng","year":"2018","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jtct.2024.09.017_bib0058","doi-asserted-by":"crossref","unstructured":"Besse K, Maiers M, Confer D, Albrecht MJBoB, Transplantation M. On modeling human leukocyte antigen\u2013identical sibling match probability for allogeneic hematopoietic cell transplantation: estimating the need for an unrelated donor source. 2016;22(3):410-7.","DOI":"10.1016\/j.bbmt.2015.09.012"},{"issue":"2","key":"10.1016\/j.jtct.2024.09.017_bib0059","doi-asserted-by":"crossref","first-page":"105.e1","DOI":"10.1016\/j.jtct.2021.10.006","volume":"28","author":"Alotaibi","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.09.017_bib0060","doi-asserted-by":"crossref","unstructured":"Zhao J, Ma L, Zheng M, Su L, Guo XJAoH. Meta-analysis of the results of haploidentical transplantation in the treatment of aplastic anemia. 2023;102(9):2565-87.","DOI":"10.1007\/s00277-023-05339-7"},{"issue":"5","key":"10.1016\/j.jtct.2024.09.017_bib0061","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1056\/NEJMoa1103975","article-title":"Horse versus rabbit antithymocyte globulin in acquired aplastic anemia","volume":"365","author":"Scheinberg","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2024.09.017_bib0062","first-page":"41","article-title":"Long-term issues after immunosuppressive therapy for aplastic anemia","volume":"98","author":"de Fontebrune","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2024.09.017_bib0063","doi-asserted-by":"crossref","DOI":"10.1007\/s12185-016-2053-8","article-title":"Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia: an Asian multicenter retrospective study","author":"Chuncharunee","year":"2016","journal-title":"Int J Hematol"},{"issue":"4","key":"10.1016\/j.jtct.2024.09.017_bib0064","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s12185-016-2053-8","article-title":"Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party","volume":"104","author":"Marsh","year":"2016","journal-title":"Int J Hematol"},{"issue":"17","key":"10.1016\/j.jtct.2024.09.017_bib0065","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1182\/blood-2010-08-304071","article-title":"A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation","volume":"117","author":"Tichelli","year":"2011","journal-title":"Blood"},{"issue":"9471","key":"10.1016\/j.jtct.2024.09.017_bib0066","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0140-6736(05)66515-4","article-title":"Aplastic anaemia","volume":"365","author":"Brodsky","year":"2005","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.jtct.2024.09.017_bib0067","first-page":"105 e1-e7","volume":"28","author":"Alotaibi","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2024.09.017_bib0068","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbmt.2010.06.011","volume":"17","author":"Peffault de Latour","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2024.09.017_bib0069","first-page":"750","article-title":"Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study","volume":"132","author":"Peffault de Latour","year":"2018","journal-title":"Blood J Am Soc Hematol"},{"issue":"5","key":"10.1016\/j.jtct.2024.09.017_bib0070","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bbmt.2013.01.023","article-title":"Excellent outcome of haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia","volume":"19","author":"Im","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2024.09.017_bib0071","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/bmt.2012.79","article-title":"A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia","volume":"47","author":"Xu","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2024.09.017_bib0072","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3324\/haematol.2017.164459","article-title":"Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia","volume":"102","author":"Kekre","year":"2017","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.jtct.2024.09.017_bib0073","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2006-09-045625","article-title":"Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia","volume":"109","author":"Scheinberg","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2024.09.017_bib0074","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1681\/ASN.2006050422","article-title":"A novel mechanism of action for anti-thymocyte globulin: induction of CD4:+: CD25:+: foxp3:+: regulatory T cells","volume":"17","author":"Lopez","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.jtct.2024.09.017_bib0075","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/bmt.2013.115","article-title":"Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation","volume":"49","author":"Marsh","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2024.09.017_bib0076","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2010-12-327536","article-title":"Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia","volume":"118","author":"Marsh","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2024.09.017_bib0077","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.bbmt.2020.06.027","article-title":"Fludarabine, campath, and low-dose cyclophosphamide (FCC(low)) with or without TBI conditioning results in excellent transplant outcomes in children with severe aplastic anemia","volume":"26","author":"Shah","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2024.09.017_bib0078","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3324\/haematol.2009.006916","article-title":"Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen","volume":"94","author":"Maury","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2024.09.017_bib0079","doi-asserted-by":"crossref","unstructured":"Iftikhar R, Anwer F, Neupane K, et al. Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies. 2021;47:100772.","DOI":"10.1016\/j.blre.2020.100772"},{"key":"10.1016\/j.jtct.2024.09.017_bib0080","doi-asserted-by":"crossref","unstructured":"Iftikhar R, Satti TM, Mahmood SK, et al. Comparison of conventional cyclophosphamide versus fludarabine-based conditioning in high-risk aplastic anemia patients undergoing matched-related donor transplantation. 2020;2(2):82.","DOI":"10.2991\/chi.d.200426.001"},{"key":"10.1016\/j.jtct.2024.09.017_bib0081","doi-asserted-by":"crossref","first-page":"1289180","DOI":"10.3389\/fmed.2023.1289180","article-title":"Peripheral blood stem cell transplantation vs. bone marrow transplantation for aplastic anemia: a systematic review and meta-analysis","volume":"10","author":"Zhang","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"10.1016\/j.jtct.2024.09.017_bib0092","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/bmt.2016.235","article-title":"Peripheral blood versus bone marrow transplant in patients with aplastic anemia, an unresolved issue","volume":"51","author":"Ghavamzadeh","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.09.017_bib0093","doi-asserted-by":"crossref","unstructured":"Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. 2007;110(4):1397-400.","DOI":"10.1182\/blood-2007-03-081596"},{"issue":"9","key":"10.1016\/j.jtct.2024.09.017_bib0094","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1182\/blood-2011-05-354001","article-title":"Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia","volume":"118","author":"Eapen","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2024.09.017_bib0095","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3324\/haematol.2011.054841","article-title":"Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups","volume":"97","author":"Bacigalupo","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2024.09.017_bib0096","doi-asserted-by":"crossref","unstructured":"Min GJ, Park S-S, Park S, et al. Bone marrow versus peripheral blood in hla-matched sibling transplantation: does the stem cell source matter in severe aplastic anemia? 2023;142:2715.","DOI":"10.1182\/blood-2023-182542"},{"issue":"8","key":"10.1016\/j.jtct.2024.09.017_bib0097","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3324\/haematol.2011.054841","article-title":"Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups","volume":"97","author":"Bacigalupo","year":"2012","journal-title":"haematologica"},{"key":"10.1016\/j.jtct.2024.09.017_bib0098","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/asheducation-2013.1.82","article-title":"Allogeneic BM transplantation for the treatment of aplastic anemia: current results and expanding donor possibilities","volume":"2013","author":"Soci\u00e9","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.jtct.2024.09.017_bib0099","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1053\/bbmt.2001.v7.pm11215697","article-title":"Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers","volume":"7","author":"Storb","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2024.09.017_bib0100","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.1016\/S2352-3026(15)00147-7","article-title":"Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1\u20132 dose de-escalation study","volume":"2","author":"Anderlini","year":"2015","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2024.09.017_bib0101","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/bjh.15066","article-title":"Paediatric amendment to adult BSH Guidelines for aplastic anaemia","volume":"180","author":"Samarasinghe","year":"2018","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.jtct.2024.09.017_bib0102","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.bbmt.2014.06.028","article-title":"Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia","volume":"20","author":"Clay","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2024.09.017_bib0103","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.bbmt.2016.12.628","article-title":"Alternative donor transplantation with high-dose post-transplantation cyclophosphamide for refractory severe aplastic anemia","volume":"23","author":"DeZern","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2024.09.017_bib0083","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood-2018-01-829630","article-title":"Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study","volume":"132","author":"Peffault de Latour","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2024.09.017_bib0104","doi-asserted-by":"crossref","first-page":"442.e1","DOI":"10.1016\/j.jtct.2024.01.072","article-title":"Upfront umbilical cord blood transplantation versus immunosuppressive therapy for pediatric patients with idiopathic severe aplastic anemia","volume":"30","author":"Zhao","year":"2024","journal-title":"Transplantat Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2024.09.017_bib0105","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3324\/haematol.2013.091074","volume":"98","author":"Gerull","year":"2013","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.jtct.2024.09.017_bib0082","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/bmt.2010.213","article-title":"Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia","volume":"46","author":"Dezern","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.09.017_bib0084","doi-asserted-by":"crossref","unstructured":"Sureda A, Carpenter PA, Bacigalupo A, et al. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT. 2024:1-6.","DOI":"10.1038\/s41409-024-02251-0"},{"issue":"2","key":"10.1016\/j.jtct.2024.09.017_bib0085","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.bbmt.2016.11.003","article-title":"Mixed T cell chimerism after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia using an alemtuzumab-containing regimen is shaped by persistence of recipient CD8 T cells","volume":"23","author":"Grimaldi","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.09.017_bib0086","doi-asserted-by":"crossref","unstructured":"Jaspers A, Baron F, Willems E, et al. Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a prospective, randomized trial. 2014;124(1):33-41.","DOI":"10.1182\/blood-2014-01-546333"},{"issue":"5","key":"10.1016\/j.jtct.2024.09.017_bib0087","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41409-017-0062-8","article-title":"The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation","volume":"53","author":"Ciurea","year":"2018","journal-title":"Bone Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724006821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724006821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T19:26:05Z","timestamp":1733167565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724006821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":101,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2666636724006821"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.09.017","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}